Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy

On March 18, Medicilon Inc. (Medicilon) and Innoforce Pharmaceuticals (Innoforce) reached a strategic collaboration, focusing on cutting-edge fields such as RNA, cell and gene therapy, and work together to open a new chapter in innovative drug research and development.

Medicilon and Innoforce Pharmaceuticals have reached a strategic collaboration to accelerate the innovative development of RNA, cell and gene therapy.webp

Two-way development, move forward together
Improve the efficiency of RNA, cell and genetic drug research and development

In the exploration of the field of biopharmaceutical, RNA, cell and gene therapy are gradually becoming emerging forces leading the development of the industry with their unique advantages and potential. These cutting-edge therapies not only open up new path for disease treatment, but also provide new opportunities for biopharmaceutical companies.

As a CRO deeply involved in the field of biopharmaceutical preclinical R&D, Medicilon keeps up with the trends and involved in cutting-edge fields such as bi/multi-specific antibodies, ADCs, mRNA vaccines, small nucleic acid drugs, PROTAC, and CGT. Medicilon has helped 421 INDs pass the approval of China's NMPA, the US FDA, the EU's EMA and the Australian TGA to enter clinical trials.

Innoforce is a global biopharmaceutical contract development and manufacturing organizations (CDMO) serving domestic and foreign clients. Focusing on areas such as RNA and cell therapy products, Innoforce is committed to providing one-stop CDMO solutions including plasmids, viral vectors, cell therapy products, RNA and LNP to advanced therapy drug partners.

Dedicated to empowering the cutting-edge areas of drug research and development, Medicilon and Innoforce have reached a strategic collaboration based on the same vision and complementary technical advantages. According to the strategic collaboration agreement, the two parties will conduct all-round strategic collaboration in business collaboration, resource sharing, global promotion, joint development and commercial licensing. This collaboration not only achieves the complementary advantages and efficient integration of the resources of both parties, but also demonstrates profound insights and firm confidence in the fields of advanced therapies such as RNA, cell and gene therapy, and will also lead the entire biopharmaceutical industry towards higher and further goals.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客